Latest news

New IP rules will stifle medical innovation in Europe, Swedish life science leaders conclude during seminar 

While Sweden has a well-developed ecosystem supporting life science companies, the global competition is fierce and it remains a struggle to put Sweden, the Nordics, and Europe on the map. The newly proposed EU pharmaceutical legislation puts European innovation at risk due to proposed changes in IP rights for new drugs, industry experts and leaders concluded during a seminar in Stockholm this summer.


Ingrid Heath - Lead instructor for the course Strategy and Business Development for Life Science Leaders.

As a partner and advisor at Adlersson Heath, Ingrid supports life science companies in the strategic and practical work to increase company value and in interactions with the capital market. With a background as vice president and policy director at SwedenBIO and editor-in-chief of Läkemedelsvärlden and Life Science Sweden, Ingrid also has broad experience from media and advocacy work in life science. She shares all this on the course Strategy and business development for life science leaders. This year is the third time that the course is held and Ingrid gives her view of what is the strength of the course.


Three quick questions for Sciety

On March 28, a seminar on raising capital for unlisted companies will take place in Stockholm, offered exclusively to SwedenBIO members. Sciety is hosting the event, which is organized in collaboration with SwedenBIO. We took the opportunity to ask Sciety's CEO Andreas Lindblom some questions before the seminar.

1 2 3 ... 40